NIKKEI 225
26,153.81 +218.19 (+0.84%) HANG SENG
21,830.35 -29.44 (-0.13%) CRUDE OIL
110.30 +1.87 (+1.72%) GOLD FUTURES
1,807.40 +5.90 (+0.33%) DOW
30,971.74 -125.52 (-0.40%) BTC-GBP
17,206.41 +601.97 (+3.63%)
Merus N.V. (MRUS)
After hours:
| Previous close | 22.64 |
| Open | 22.60 |
| Bid | 22.35 x 1000 |
| Ask | 22.32 x 900 |
| Day's range | 21.33 - 22.91 |
| 52-week range | 13.47 - 33.09 |
| Volume | |
| Avg. volume | 371,356 |
| Market cap | 974.619M |
| Beta (5Y monthly) | 1.01 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.25 |
| Earnings date | 14 Mar 2022 - 18 Mar 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 41.56 |
- Simply Wall St.
Merus (NASDAQ:MRUS) Is In A Strong Position To Grow Its Business
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
- Globe Newswire
Merus Presents Clinical Data on Zenocutuzumab (Zeno) in NRG1-fusion (NRG1+) Cancer at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting (Oral Abstract)
34% overall response rate in 79 evaluable patients with measurable disease9.1 months median duration of responseTumor reduction in 70% of patientsZeno observed to be very well-toleratedPotential new standard of care for patients with NRG1+ cancerInvestor call to discuss clinical results on Sunday, June 5 at 6:00 p.m. CT UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 05, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology com
- Zacks
Does Merus N.V. (MRUS) Have the Potential to Rally 113% as Wall Street Analysts Expect?
The mean of analysts' price targets for Merus N.V. (MRUS) points to an 113.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
